tradingkey.logo

Precipio Inc

PRPO
View Detailed Chart

14.010USD

-0.450-3.11%
Market hours ETQuotes delayed by 15 min
21.08MMarket Cap
LossP/E TTM

Precipio Inc

14.010

-0.450-3.11%
Intraday
1m
30m
1h
D
W
M
D

Today

-3.11%

5 Days

-4.69%

1 Month

+16.27%

6 Months

+110.68%

Year to Date

+152.90%

1 Year

+177.43%

View Detailed Chart

Agency Rating

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

1m
15m
30m
1h
D
W
M
1m
15m
30m
D
Neutral
Sell(4)
Neutral(4)
Buy(5)
Indicators
Sell(1)
Neutral(4)
Buy(2)
Indicators
Value
Direction
MACD(12,26,9)
-0.361
Neutral
RSI(14)
58.186
Neutral
STOCH(KDJ)(9,3,3)
66.012
Neutral
ATR(14)
0.805
Low Volatility
CCI(14)
-16.125
Neutral
Williams %R
41.224
Buy
TRIX(12,20)
0.746
Sell
StochRSI(14)
69.744
Buy
Moving Average
Sell(3)
Neutral(0)
Buy(3)
Indicators
Value
Direction
MA5
14.410
Sell
MA10
14.334
Sell
MA20
14.678
Sell
MA50
12.357
Buy
MA100
9.390
Buy
MA200
7.916
Buy

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. It develops and sells diagnostic products, reagents and services that improve the accuracy and efficiency of diagnostics, and lead to fewer misdiagnoses. The Company’s technologies include HemeScreen and IV-Cell. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its technology enables testing to be completed in one rapid scanning process. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
Ticker SymbolPRPO
CompanyPrecipio Inc
CEOMr. Ilan Danieli
Websitehttps://www.precipiodx.com/
KeyAI